MA49256A - Schémas posologiques comprenant un antagoniste de l'hormone de libération des gonadotrophines pour le traitement de l'endométriose - Google Patents
Schémas posologiques comprenant un antagoniste de l'hormone de libération des gonadotrophines pour le traitement de l'endométrioseInfo
- Publication number
- MA49256A MA49256A MA049256A MA49256A MA49256A MA 49256 A MA49256 A MA 49256A MA 049256 A MA049256 A MA 049256A MA 49256 A MA49256 A MA 49256A MA 49256 A MA49256 A MA 49256A
- Authority
- MA
- Morocco
- Prior art keywords
- endometriosis
- treatment
- hormone antagonist
- dosage schedules
- release hormone
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Gynecology & Obstetrics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Apparatus For Radiation Diagnosis (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762515268P | 2017-06-05 | 2017-06-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA49256A true MA49256A (fr) | 2021-05-26 |
Family
ID=62620835
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA049256A MA49256A (fr) | 2017-06-05 | 2018-06-05 | Schémas posologiques comprenant un antagoniste de l'hormone de libération des gonadotrophines pour le traitement de l'endométriose |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11980621B2 (enExample) |
| EP (1) | EP3634418A1 (enExample) |
| JP (2) | JP7348171B2 (enExample) |
| KR (2) | KR102839190B1 (enExample) |
| CN (1) | CN110996956A (enExample) |
| AU (2) | AU2018280742B2 (enExample) |
| CA (1) | CA3066190A1 (enExample) |
| EA (1) | EA201992612A1 (enExample) |
| MA (1) | MA49256A (enExample) |
| MX (1) | MX2019014483A (enExample) |
| SG (1) | SG11201911598WA (enExample) |
| WO (1) | WO2018224498A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018060501A2 (en) | 2016-09-30 | 2018-04-05 | Myovant Sciences Gmbh | Methods of treating uterine fibroids and endometriosis |
| EA201992612A1 (ru) | 2017-06-05 | 2020-05-20 | Обсева С.А. | Схемы применения антагониста гонадотропин-высвобождающего гормона для лечения эндометриоза |
| DK3634419T3 (da) | 2017-06-05 | 2025-03-31 | Kissei Pharmaceutical | Doseringsregime omfattende en gonadotropin-frigørende hormon-antagonist til behandling af fibromer i uterus og reduktion af menstruationsblodtab |
| MA54058A (fr) | 2018-10-29 | 2021-09-08 | ObsEva SA | Compositions et méthodes de traitement de l'endométriose interne et de l'endométriose rectovaginale |
| AU2020325655B2 (en) * | 2019-08-08 | 2025-09-11 | Kissei Pharmaceutical Co., Ltd. | Compositions and methods for the treatment of estrogen-dependent disorders |
| CN113384581B (zh) * | 2020-03-12 | 2023-11-14 | 成都倍特药业股份有限公司 | 一种包含促性腺激素释放激素拮抗剂的药物组合物 |
| BR112022023937A2 (pt) | 2020-05-29 | 2022-12-27 | Myovant Sciences Gmbh | Formas de dosagem oral sólidas de combinação de antagonistas do hormônio liberador de gonadotropina |
| WO2022101303A1 (en) * | 2020-11-11 | 2022-05-19 | Myovant Sciences Gmbh | Methods of administering relugolix |
| WO2022179469A1 (zh) * | 2021-02-23 | 2022-09-01 | 南京明德新药研发有限公司 | 噻吩并嘧啶二酮类化合物及其应用 |
| CN115232144B (zh) * | 2021-04-22 | 2024-04-02 | 长春金赛药业有限责任公司 | 含氮稠环类衍生物、药物组合物及其制备方法和应用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5342760A (en) | 1992-06-10 | 1994-08-30 | Abbott Laboratories | Determination of estradiol by competitive immunoassay |
| US5663054A (en) | 1995-03-03 | 1997-09-02 | Abbott Laboratories | Determination of steroids by competitive immunoassay |
| US7109171B2 (en) | 2000-02-28 | 2006-09-19 | Praecis Pharmaceuticals Inc. | Methods for treating FSH related conditions with GnRH antagonists |
| PT1300398E (pt) | 2000-07-05 | 2006-07-31 | Astellas Pharma Inc | Processos e composicoes para terapias do cancro, utilizando genes que codificam o interferao-beta |
| CN101153042A (zh) | 2003-01-29 | 2008-04-02 | 武田药品工业株式会社 | 噻吩并嘧啶化合物及其用途 |
| EP1646389B1 (en) | 2003-07-07 | 2008-09-10 | Neurocrine Biosciences, Inc. | Pyrimidine-2,4-dione derivatives as gonadotropin-releasing hormone receptor antagonists |
| SI1864976T1 (sl) | 2005-03-31 | 2012-12-31 | Astellas Pharma Inc. | Propan-1,3-dionski derivat ali njegova sol |
| RU2418803C2 (ru) * | 2005-10-19 | 2011-05-20 | Киссеи Фармасьютикал Ко., Лтд. | Конденсированное гетероциклическое производное, содержащая его лечебная композиция и ее применение в медицине |
| US8765948B2 (en) | 2007-11-07 | 2014-07-01 | Neurocrine Biosciences, Inc. | Processes for the preparation of uracil derivatives |
| EP2535342B1 (en) | 2010-02-10 | 2014-08-06 | Kissei Pharmaceutical Co., Ltd. | Salt of fused heterocyclic derivative and crystal thereof |
| EA201491344A1 (ru) | 2012-01-16 | 2015-04-30 | Байер Интеллектуэль Проперти Гмбх | Производные спироиндолина в качестве антагонистов рецептора гонадотропин-рилизинг гормона |
| WO2013126517A1 (en) | 2012-02-21 | 2013-08-29 | Northwestern University | Anti-mullerian hormone detection in whole blood |
| CN104603114B (zh) | 2012-09-07 | 2017-06-20 | 安斯泰来制药株式会社 | 磺酰脒化合物的制造方法 |
| JP6268093B2 (ja) * | 2012-09-14 | 2018-01-24 | キッセイ薬品工業株式会社 | 縮合複素環誘導体の製造方法およびその製造中間体 |
| SMT202200255T1 (it) | 2012-09-28 | 2022-07-21 | Takeda Pharmaceuticals Co | Forma cristallina di 1-(4-1-(2,6-difluorobenzil)-5-dimetilamminometil-3-(6-metossipiridazin-3-il)-2,4-diosso-1,2,3,4-tetraidrotieno(2,3-d)-pirimidin-6il)fenil)-3-metossiurea |
| EP4223298A3 (en) | 2013-03-15 | 2023-08-16 | AbbVie Inc. | Compositions for use in treating heavy menstrual bleeding |
| AR095785A1 (es) | 2013-04-09 | 2015-11-11 | Bayer Pharma AG | Derivados de espiroindolina y composiciones farmacéutica de los mismos |
| WO2017040841A1 (en) | 2015-09-01 | 2017-03-09 | Abbvie Inc. | Methods of administering elagolix |
| BR112019002513A2 (pt) | 2016-08-08 | 2019-05-14 | Kissei Pharmaceutical Co., Ltd. | uso e dosagem de agentes terapêuticos para endometriose |
| WO2018060501A2 (en) | 2016-09-30 | 2018-04-05 | Myovant Sciences Gmbh | Methods of treating uterine fibroids and endometriosis |
| DK3634419T3 (da) | 2017-06-05 | 2025-03-31 | Kissei Pharmaceutical | Doseringsregime omfattende en gonadotropin-frigørende hormon-antagonist til behandling af fibromer i uterus og reduktion af menstruationsblodtab |
| EA201992612A1 (ru) | 2017-06-05 | 2020-05-20 | Обсева С.А. | Схемы применения антагониста гонадотропин-высвобождающего гормона для лечения эндометриоза |
| JP7459086B2 (ja) | 2018-11-07 | 2024-04-01 | キッセイ薬品工業株式会社 | エストロゲン依存性障害の治療のための組成物及び方法 |
-
2018
- 2018-06-05 EA EA201992612A patent/EA201992612A1/ru unknown
- 2018-06-05 AU AU2018280742A patent/AU2018280742B2/en active Active
- 2018-06-05 EP EP18731378.8A patent/EP3634418A1/en active Pending
- 2018-06-05 WO PCT/EP2018/064768 patent/WO2018224498A1/en not_active Ceased
- 2018-06-05 MX MX2019014483A patent/MX2019014483A/es unknown
- 2018-06-05 MA MA049256A patent/MA49256A/fr unknown
- 2018-06-05 KR KR1020197038977A patent/KR102839190B1/ko active Active
- 2018-06-05 US US16/619,776 patent/US11980621B2/en active Active
- 2018-06-05 SG SG11201911598WA patent/SG11201911598WA/en unknown
- 2018-06-05 KR KR1020257024754A patent/KR20250117836A/ko active Pending
- 2018-06-05 JP JP2020516959A patent/JP7348171B2/ja active Active
- 2018-06-05 CA CA3066190A patent/CA3066190A1/en active Pending
- 2018-06-05 CN CN201880050650.3A patent/CN110996956A/zh active Pending
-
2023
- 2023-05-23 JP JP2023084336A patent/JP7657855B2/ja active Active
-
2024
- 2024-03-14 AU AU2024201701A patent/AU2024201701B2/en active Active
- 2024-04-12 US US18/634,241 patent/US20240293414A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018280742A1 (en) | 2020-01-30 |
| MX2019014483A (es) | 2020-08-17 |
| JP2020522571A (ja) | 2020-07-30 |
| JP7348171B2 (ja) | 2023-09-20 |
| AU2024201701B2 (en) | 2025-04-10 |
| JP7657855B2 (ja) | 2025-04-07 |
| AU2024201701A1 (en) | 2024-04-04 |
| AU2018280742B2 (en) | 2023-12-21 |
| EP3634418A1 (en) | 2020-04-15 |
| US20240293414A1 (en) | 2024-09-05 |
| SG11201911598WA (en) | 2020-01-30 |
| KR102839190B1 (ko) | 2025-07-28 |
| US20200138819A1 (en) | 2020-05-07 |
| CN110996956A (zh) | 2020-04-10 |
| CA3066190A1 (en) | 2018-12-13 |
| JP2023113715A (ja) | 2023-08-16 |
| US11980621B2 (en) | 2024-05-14 |
| KR20200027481A (ko) | 2020-03-12 |
| KR20250117836A (ko) | 2025-08-05 |
| WO2018224498A1 (en) | 2018-12-13 |
| EA201992612A1 (ru) | 2020-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR25C1001I1 (fr) | Compositions d'anticorps pour le traitement de tumeurs | |
| EP3807267A4 (en) | THYROID HORMONE RECEPTOR AGONISTS AND USES THEREOF | |
| MA49279A (fr) | Compositions d'anticorps optimisées pour le traitement de troubles oculaires | |
| MA45481A (fr) | Utilisation d'exosomes pour le traitement de maladies | |
| EP3645040A4 (en) | USE OF ANTI-FAM19A5 ANTIBODIES FOR CANCER TREATMENT | |
| EP3645039A4 (en) | USE OF ANTI-FAM19A5 ANTIBODIES TO TREAT FIBROSIS | |
| EP3574907C0 (en) | AN NK1/NK3 RECEPTOR ANTAGONIST FOR THE TREATMENT OF SEX HORMONE DEPENDENT DISEASES | |
| EP3612566A4 (en) | CD14 ANTAGONIST ANTIBODIES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | |
| EP3468532A4 (en) | DISTRIBUTION DEVICE AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF RHINITIS | |
| EP3621600A4 (en) | METHODS FOR TREATMENT OF RECIDIVING GLIOBLASTOMA (RGBM) | |
| EP3319534A4 (en) | SYSTEMS AND METHOD FOR TREATING AND PREVENTING BELLY DYSFUNCTION IN WOMEN | |
| MA43825A (fr) | Schémas posologiques pour le traitement d'infections fongiques | |
| SG11201911598WA (en) | Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis | |
| EP3877418A4 (en) | DOSING REGIME OF AN ANTI-TIGIT ANTIBODY FOR THE TREATMENT OF CANCER | |
| EP3684478A4 (en) | CONNECTOR OF A FALL LOCKING DEVICE | |
| EP3773221A4 (en) | TREATMENT OF HYDROCEPHALUS | |
| EP3344325A4 (en) | LOCAL ADMINISTRATION OF MEDICAMENTS FOR THE TREATMENT OF ASTHMA | |
| EP3541379A4 (en) | COMPOSITIONS FOR THE TREATMENT OF HYPERTONIA | |
| EP3700489A4 (en) | EXOSKELETAL DEVICE FOR REHABILITATION OF THE UPPER LIMBS | |
| EP3498280A4 (en) | ADMINISTRATION AND PHARMACEUTICAL FORM OF A THERAPEUTIC FOR ENDOMETRIOSIS | |
| EP3877402A4 (en) | COMBINATION TREATMENT AGAINST RESISTANT HYPERTENSION | |
| EP3452491A4 (en) | QUANTITATIVE PROFILING OF PROGESTERONMETABOLITES FOR THE PREDICTION OF SPONTANEOUS EARLY BIRTHS | |
| MA46086A (fr) | Schéma posologique pour le traitement de tumeurs solides | |
| MA44700A (fr) | Combinaison d'un anticorps anti-il-10 et d'un oligonucléotide de type cpg-c pour le traitement du cancer | |
| MA54511A (fr) | Composition ophtalmique nutraceutique pour le traitement de pathologies retiniennes a composante neovasculaire |